(Answered) a. Novo Nordisk began producing only insulin and then transformed itself into a widely known weight…

Written by

in

a.
Novo Nordisk began producing only insulin and then transformed itself into a widely known weight loss product in the pharmaceutical industry. The following are three points worth noticing:Novo Nordisk’s decision to extend its focus from curing diabetes into fighting obesity is a great change in the corporate industry. Obesity is a problem with over 40% of American adults being obese and is increasing worldwide. The company is attacking a huge market with hundreds and millions of potential patients. By aligning its own mission to public goals such as reducing cardiovascular health issues. Novo Nordisk created a pathway for the weight loss health industry. It is not just about making and selling a new drug but also to partner up in the public health arena.
The full-scale approach to manufacturing and infrastructure suggests how a company is handling the current situation. It is investing more than 6 billion to build new plants and also is increasing the staff by thousands and going global as well. They are increasing its presence in the US and taking over tiny biotech industries. This indicates the presence of long-term demand and a desire for market share growth in comparison to any other pharmaceutical companies.
The company’s attention to its own culture and the Novo Nordisk Way emphasizes patient-centered cared and ethical decision making. This is notable for many as it indicates the patient centered care and ethical decision making. It is not just about selling products but to also understand the reason as to why the product is important. The processes are put in place to increase growth and long term success.
b.
Novo Nordisk is vulnerable due to the tradeoff of whether they are overinvesting in a market where the future is unknown. By 2032, U.S. patents on their leading drugs are set to expire and there must be multiple rivals developing their own GLP-1 based therapies. The market could possibly get overcrowded in the future and in a fast pace. If weight loss drugs turn generic as most insulin drugs eventually did, Novo Nordisk is at risk to face major competition in addition to falling margins. Also, while their current investments are making sense due to the demand, there is always the risk that they have overspent on the infrastructure that will later change. Also, because the drug is new there is no way of telling what the long term affects may be in the future.
c.
From the corporate governance standpoint, the hefty price tag for Ozempic of almost $1,000 a month in the USA raises serious ethical points and regulatory questions. Novo Nordisk may argue that such drugs save long-term healthcare costs by cutting obesity related illnesses, but developing access remains to those dependent on their insurances. This places unnecessary stress on the likes of public programs like Medicare, and does not help the underinsured or uninsured patients. do you agree why or why not?

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *